33%
of all deaths are due to CVD1
4/5
deaths from CVDs are due to heart attacks1
33%
of all deaths are due to CVD1
4/5
deaths from CVDs are due to heart attacks1
Get in touch!
Want to learn about how we’re taking on cardiovascular disease?
About our partnerships
Contact us
Read more
Pipeline
Our pipeline consists of products based on our tissue production platform, including tissue-based therapeutics for type 1 diabetes treatment, and cardiac toxicity and kidney disease screening models.
Read more
our platform
Learn more about Nexocyte, Fluicell’s universal tissue production platform, based on our high-resolution single-cell bioprinting technology Biopixlar.
Read more